%A Tan, Chee-Kiat %T Entecavir : A review %9 Review Article %D 2006 %J Hepatitis B Annual %P 35-53 %V 3 %N 1 %U https://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2006;volume=3;issue=1;spage=35;epage=53;aulast=Tan %8 January 1, 2006 %X Entecavir is the newest and most potent nucleoside analog to be licensed worldwide for the treatment of chronic hepatitis B infection. It has been shown to be more effective than lamivudine and adefovir in direct head-to-head comparison trials. It is also useful in the treatment of lamivudine-refractory patients. Entecavir is safe with no significant difference in adverse effects compared to lamivudine and adefovir. Available data for up to 2 years of continuous therapy showed no development of viral resistance in nucleos(t)ide-naοve patients. Resistance to entecavir occurs only in patients previously exposed to lamivudine and occurs at a rate of 9% after 2 years of continuous therapy with entecavir. %0 Journal Article %I Wolters Kluwer Medknow Publications %@ 0972-9747